Special Issue

Interferon Signaling in Viral Pathogenesis

Message from the Guest Editor

Recent findings have revealed the dual roles of IFN-I signaling in virus infection and pathogenesis: it plays a critical role to suppress acute virus infection and to set the host immune anti-viral program. During chronic infection, however, persistent IFN-I signaling contributes to virus-associated hyper-inflammation, immune exhaustion, and virus persistence. In this Special Issue, we will focus on the most recent advances in understanding the mechanism of virus-host cell interaction in IFN induction, with a special emphasis on how IFN-I may play both a positive and a negative role during acute and persistent virus infection. We will also focus on new developments on targeting IFN signaling in modulating immunotherapy of virus infection, autoimmune diseases, and cancer.

Guest Editor

Prof. Dr. Lishan Su

Institute of Human Virology, Departments of Pharmacology and Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 20201, USA

Deadline for manuscript submissions

31 March 2026



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/212692

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

